Research
Hormonal
Lifestyle interventions for obesity typically result in modest long-term weight loss (5-10%) and high rates of weight regain due to potent biological adaptations, specifically increased appetite and reduced energy expenditure.
If you lose weight through diet and exercise, expect your body to fight back with increased hunger and a slower metabolism. This is a normal biological response, not a failure of willpower. To maintain loss, you may need ongoing support or pharmacological intervention to counteract these specific hormonal signals.
StrongQualifiesHIGH confidence
Weight loss through lifestyle changes results in modest weight loss long-term possibly due to compensatory biological adaptations (increased appetite and reduced energy expenditure).
Why this rating
Supported by multiple large-scale trials (Look AHEAD, DROPLET) and mechanistic studies cited in the review.
Source
New therapies for obesity
Dimitris Papamargaritis et al. · Cardiovascular Research · 2022
DOI 10.1093/cvr/cvac176
narrative_reviewCited 69×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide 2.4mg weekly induces significantly greater weight loss (mean 14.9%) compared to lifestyle interventions alone (mean 2.4%) in adults without diabetes.Strong
- Bariatric surgery (specifically Roux-en-Y gastric bypass and sleeve gastrectomy) consistently achieves sustained weight loss of 25-30% and improves cardiovascular outcomes, serving as the current gold standard for efficacy.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →